Eligo Bioscience SAS
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eligo Bioscience SAS
With its first microbiome fund completing its investment period, French venture capitalist Seventure Partners has raised more than €100m of a €200m target for its second microbiome-focused fund.
Genocea shifts to preclinical neoantigen-based cancer vaccines rather than advance a Phase III-ready herpes program on its own and Mateon gives up on its lead drug as placebo outperforms. Also, Juno tops recent public company financings and new VC funds back early-stage firms.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a monthly review of emerging In Vitro Diagnostic, Medical Device, and Pharmaceutical companies that have received venture funding. This month’s column covers deals announced July through August 2015.
There is growing interest in the gut microbiome as a source of new therapies across a wide range of diseases. Although it is still an emerging field, pharmaceutical firms and other investors are engaging, with more expected to follow.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
- Nanotechnology, Chips, etc.